Patricia Frech

Title: Patricia Frech: Innovator in Thrombin Inhibition

Introduction

Patricia Frech is a notable inventor based in King of Prussia, PA (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of thrombin inhibitors. Her work is essential in addressing thrombotic occlusions, which can lead to serious health complications.

Latest Patents

Patricia Frech holds 1 patent for her invention titled "Pyrazinone thrombin inhibitors." This patent includes compounds that are effective in inhibiting thrombin and associated thrombotic occlusions. The compounds are selected from a specific group, including 3-Fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide polymorphic crystalline Anhydrous Form B, 3-Fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide polymorphic crystalline form Type A Monohydrate, and 3-Fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide polymorphic crystalline form Type B monohydrate, or a pharmaceutically acceptable salt thereof.

Career Highlights

Patricia is currently employed at Merck & Co., Inc., where she continues to advance her research in pharmaceutical innovations. Her work at Merck has positioned her as a key player in the development of new therapeutic agents.

Collaborations

Throughout her career, Patricia has collaborated with notable colleagues, including Daniel J Rush and Cameron Cowden. These collaborations have enhanced her research and contributed to the success of her inventions.

Conclusion

Patricia Frech is a pioneering inventor whose work in thrombin inhibitors is making a significant impact in the pharmaceutical industry. Her contributions are vital for the development of effective treatments for thrombotic conditions.